What's Going On With Vivos Therapeutics Stock?
Portfolio Pulse from Erica Kollmann
Vivos Therapeutics, Inc. (NASDAQ:VVOS) shares dropped after filing a prospectus for the resale of up to 1.73 million shares by selling shareholders. The company could receive $8.4 million if all warrants are exercised. Vivos also announced Medicare reimbursement approval for its CARE oral medical devices and reported Q4 losses of $3.05 per share, missing estimates by 59.69%, with sales of $3.248 million also missing estimates.
April 09, 2024 | 4:36 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Vivos Therapeutics shares declined following a prospectus filing for resale of shares, missed Q4 earnings, and regulatory approval for Medicare reimbursement.
The filing for the resale of shares typically dilutes the value of existing shares, leading to a negative impact on stock price. However, the approval for Medicare reimbursement could be seen as positive news. The significant miss in Q4 earnings further pressures the stock.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100